OLAPLEX Holdings, Inc. has made its first acquisition in more than ten years since launch, buying Boston -based biotech company Purvala Bioscience in a move designed to supercharge its science pipeline and next-generation bond-building innovation.
The deal marks a strategic step beyond traditional haircare into bioinspired technologies that can power future health and beauty applications. Biotech meets bond-building leadership Founded in 2020 by Dr. Bradley Olsen , Dr. Justin Paloni, and colleagues, Purvala
focuses on developing transformative bioinspired technologies with uses across the health and beauty industries. The company creates high-performing molecules inspired by naturally occurring biological structures, bringing deep materials science expertise into OLAPLEX’s orbit. In addition to his leadership role at Purvala , Dr.
Olsen serves as a Professor of Chemical Engineering at MIT , underscoring the scientific depth behind the platform. For OLAPLEX , the acquisition plugs advanced biotech capabilities into a brand already known for its patented bond-building technology and science-first positioning in professional haircare.
OLAPLEX leans into disruptive science The acquisition is also a brand statement: OLAPLEX is returning to its roots in breakthrough formulation and professional-grade innovation. Since launch, the company has been defined by its bond-building approach, which reshaped prestige haircare and salon services.
“Since the very beginning, OLAPLEX was founded on the concept of innovation with groundbreaking bond technology that empowered stylists and their clients to achieve transformative results,” OLAPLEX CEO Amanda Baldwin said . “And scientific breakthroughs…
